PF-07799933
- Generic Name
- PF-07799933
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 124
- Registration Number
- NCT05538130
- Locations
- 🇺🇸
MSK Basking Ridge., Basking Ridge, New Jersey, United States
🇺🇸MSK Monmouth., Middletown, New Jersey, United States
🇺🇸MSK Bergen., Montvale, New Jersey, United States
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 156
- Registration Number
- NCT05355701
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Clinical and Translational Research Center (CTRC), Aurora, Colorado, United States
🇺🇸Clinical And Translational Research Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath